Point Of Care Diagnostics Market
Description
Point Of Care Diagnostics Market Summary
The global point of care diagnostics market size was estimated at USD 21.79 billion in 2025 and is projected to reach USD 29.94 billion by 2033, growing at a CAGR of 4.07% from 2026 to 2033. The increasing geriatric population and the ability of point of care (POC) diagnostic tests to provide immediate results are expected to fuel market growth.
Furthermore, increasing adaptability of mobile diagnostic devices in middle-income countries is also one of the key factors for the growth of point of care testing. In addition, the rise in funding from government & private institutions is a key trend driving the growth of this market. For instance, in October 2025, the Biomedical Advanced Research and Development Authority (BARDA) awarded funding to Beckman Coulter to validate the effectiveness of the biomarker to detect MIS-C with a large, multi-center clinical trial. In addition, the market expansion is primarily driven by the ongoing introduction of new products, with leading companies consistently introducing advanced coagulation testing devices that cater to the evolving needs of healthcare providers and patients, offering enhanced features like precision and user-friendly interfaces. For instance, in February 2024, Roche introduced three new coagulation tests for oral Factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, in countries accepting the CE mark. These tests could aid clinical decision-making in patients treated with direct oral anticoagulants for systemic embolism, stroke prevention, and venous thromboembolism prevention & treatment.
The increasing prevalence of genetic disorders is likely to drive the diagnostics market in the coming years. According to a report published by the CDC, congenital heart defects were the most common birth defects in the U.S., affecting approximately 1% of births every year. Early detection of genetic variations via prenatal testing can help in rapid disease diagnosis, prevention, and selection of suitable treatment. Changing lifestyle and environmental factors are increasing the incidence of genetic diseases. The incidence of breast and ovarian cancers is increasing in many regions. For instance, according to the Breast Cancer Research Foundation, in 2023, approximately 300,590 people are expected to be diagnosed with breast cancer in the U.S. Thus, the growing incidence of various diseases is likely to boost the market over the forecast period.
Moreover, the geriatric population is rapidly increasing across the globe. According to a UN report, in 2020, there were about 727 million people aged 65 & above globally. In addition, the number of individuals aged 80 and above is projected to double by 2050, which is over 1.5 billion. Aging has become a substantial risk factor for numerous diseases, including obesity and diabetes, which, in turn, significantly increases the risk of infectious diseases. The geriatric population is susceptible to numerous diseases such as cancer, cardiovascular diseases, obesity, neurological disorders, and diabetes. Thus, the growing geriatric population globally is anticipated to be a high-impact rendering driver of the point of care diagnostics market.
Global Point Of Care Diagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care diagnostics market report based on product, end use, and region.
The global point of care diagnostics market size was estimated at USD 21.79 billion in 2025 and is projected to reach USD 29.94 billion by 2033, growing at a CAGR of 4.07% from 2026 to 2033. The increasing geriatric population and the ability of point of care (POC) diagnostic tests to provide immediate results are expected to fuel market growth.
Furthermore, increasing adaptability of mobile diagnostic devices in middle-income countries is also one of the key factors for the growth of point of care testing. In addition, the rise in funding from government & private institutions is a key trend driving the growth of this market. For instance, in October 2025, the Biomedical Advanced Research and Development Authority (BARDA) awarded funding to Beckman Coulter to validate the effectiveness of the biomarker to detect MIS-C with a large, multi-center clinical trial. In addition, the market expansion is primarily driven by the ongoing introduction of new products, with leading companies consistently introducing advanced coagulation testing devices that cater to the evolving needs of healthcare providers and patients, offering enhanced features like precision and user-friendly interfaces. For instance, in February 2024, Roche introduced three new coagulation tests for oral Factor Xa inhibitors, rivaroxaban, apixaban, and edoxaban, in countries accepting the CE mark. These tests could aid clinical decision-making in patients treated with direct oral anticoagulants for systemic embolism, stroke prevention, and venous thromboembolism prevention & treatment.
The increasing prevalence of genetic disorders is likely to drive the diagnostics market in the coming years. According to a report published by the CDC, congenital heart defects were the most common birth defects in the U.S., affecting approximately 1% of births every year. Early detection of genetic variations via prenatal testing can help in rapid disease diagnosis, prevention, and selection of suitable treatment. Changing lifestyle and environmental factors are increasing the incidence of genetic diseases. The incidence of breast and ovarian cancers is increasing in many regions. For instance, according to the Breast Cancer Research Foundation, in 2023, approximately 300,590 people are expected to be diagnosed with breast cancer in the U.S. Thus, the growing incidence of various diseases is likely to boost the market over the forecast period.
Moreover, the geriatric population is rapidly increasing across the globe. According to a UN report, in 2020, there were about 727 million people aged 65 & above globally. In addition, the number of individuals aged 80 and above is projected to double by 2050, which is over 1.5 billion. Aging has become a substantial risk factor for numerous diseases, including obesity and diabetes, which, in turn, significantly increases the risk of infectious diseases. The geriatric population is susceptible to numerous diseases such as cancer, cardiovascular diseases, obesity, neurological disorders, and diabetes. Thus, the growing geriatric population globally is anticipated to be a high-impact rendering driver of the point of care diagnostics market.
Global Point Of Care Diagnostics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care diagnostics market report based on product, end use, and region.
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Glucose Testing
- Hb1Ac Testing
- Coagulation Testing
- Fertility/Pregnancy
- Infectious Disease
- HIV POC
- Clostridium Difficile POC
- HBV POC
- Pneumonia or Streptococcus Associated Infections
- Respiratory Syncytial Virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and Drug-resistant TB POC
- HSV POC
- COVID-19
- Other Infectious Diseases
- Cardiac Markers
- Thyroid Stimulating Hormone
- Hematology
- Primary Care Systems
- Decentralized Clinical Chemistry
- Feces
- Lipid Testing
- Cancer Marker
- Blood Gas/Electrolytes
- Ambulatory Chemistry
- Drug of Abuse (DOA) Testing
- Autoimmune Diseases
- Urinalysis/Nephrology
- End-use Outlook (Revenue, USD Billion, 2021 - 2033)
- Clinics
- Pharmacy & Retail Clinics
- Physician Office
- Urgent Care Clinics
- Non-practice Clinics
- Hospitals
- Home
- Assisted Living Healthcare Facilities
- Laboratory
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
300 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Regional Scope
- 1.4. Estimates and Forecast Timeline
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR’s Internal Database
- 1.7. Details of primary research
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity flow analysis (Model 1)
- 1.9.1.1. Approach 1: Commodity flow approach
- 1.9.2. Volume price analysis (Model 2)
- 1.9.2.1. Approach 2: Volume price analysis
- 1.10. Research Scope and Assumptions
- 1.10.1. List of Secondary Sources
- 1.10.2. List of Primary Sources
- 1.10.3. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. End Use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Point Of Care Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Introduction of CLIA waived tests
- 3.2.1.2. Rise in funding from government and private institutions
- 3.2.1.3. Growing geriatric population base
- 3.2.1.4. Growing prevalence of target diseases
- 3.2.1.5. Growing demand for home healthcare and the introduction of advanced technology enabled products
- 3.2.2. Market restraint analysis
- 3.2.2.1. High procedure costs coupled with limited adoption of POC devices in certain emerging regions
- 3.2.2.2. Presence of ambiguous regulatory as well as reimbursement framework for primary care setting
- 3.2.3. Market challenge analysis
- 3.2.3.1. POC device pose challenges in maintaining the quality standards
- 3.2.4. Market opportunity analysis
- 3.3. Point of Care Diagnostics Market Analysis Tools
- 3.3.1. Porter’s Analysis
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Legal landscape
- 3.4. Reimbursement Overview of IVDs and LDTs
- 3.5. Pricing Analysis
- Chapter 4. Point Of Care Diagnostics Market: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Segment Dashboard
- 4.3. Global Point Of Care Diagnostics Market by Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 4.4.1. Glucose Testing
- 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.2. Hb1Ac Testing
- 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.3. Coagulation Testing
- 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.4. Fertility/Pregnancy Testing
- 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5. Infectious Disease
- 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.2. HIV POC
- 4.4.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.3. Clostridium Difficile POC
- 4.4.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.4. HBV POC
- 4.4.5.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.5. Pneumonia or Streptococcus Associated Infections
- 4.4.5.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.6. Respiratory Syncytial Virus (RSV) POC
- 4.4.5.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.7. HPV POC
- 4.4.5.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.8. Influenza/Flu POC
- 4.4.5.8.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.9. HCV POC
- 4.4.5.9.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.10. MRSA POC
- 4.4.5.10.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.11. TB and drug resistant TB POC
- 4.4.5.11.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.12. HSV POC
- 4.4.5.12.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.13. COVID-19
- 4.4.5.13.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.5.14. Other infectious diseases
- 4.4.5.14.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.6. Cardiac Markers
- 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.7. Thyroid Stimulating Hormone
- 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.8. Hematology
- 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.9. Primary Care Systems
- 4.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.10. Decentralized Clinical Chemistry
- 4.4.10.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.11. Feces
- 4.4.11.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.12. Lipid Testing
- 4.4.12.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.13. Cancer Marker
- 4.4.13.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.14. Blood Gas/Electrolytes
- 4.4.14.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.15. Ambulatory Chemistry
- 4.4.15.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.16. Drug of Abuse (DOA) Testing
- 4.4.16.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.17. Autoimmune diseases
- 4.4.17.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 4.4.18. Urinalysis/Nephrology
- 4.4.18.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- Chapter 5. Point Of Care Diagnostics Market: End Use Estimates & Trend Analysis
- 5.1. End Use Market Share, 2025 & 2033
- 5.2. Segment Dashboard
- 5.3. Global Point Of Care Diagnostics Market by End Use Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 5.4.1. Clinics
- 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD billion)
- 5.4.1.2. Pharmacy & Retail Clinics
- 5.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 5.4.1.3. Physician Office
- 5.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 5.4.1.4. Urgent Care Clinics
- 5.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 5.4.1.5. Non-practice Clinics
- 5.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 5.4.2. Hospitals
- 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 5.4.3. Home
- 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 5.4.4. Assisted Living Healthcare Facilitates
- 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- 5.4.5. Laboratory
- 5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
- Chapter 6. Point Of Care Diagnostics Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2025 & 2033
- 6.2. Regional Market Dashboard
- 6.3. Global Regional Market Snapshot
- 6.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 6.5. North America
- 6.5.1. U.S.
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.5.2. Canada
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.5.3. Mexico
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6. Europe
- 6.6.1. Germany
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.2. UK
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.3. France
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework/ reimbursement structure
- 6.6.3.3. Competitive scenario
- 6.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.4. Italy
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework/ reimbursement structure
- 6.6.4.3. Competitive scenario
- 6.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.5. Spain
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Regulatory framework/ reimbursement structure
- 6.6.5.3. Competitive scenario
- 6.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.6. Russia
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Regulatory framework/ reimbursement structure
- 6.6.6.3. Competitive scenario
- 6.6.6.4. Russia market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.7. Norway
- 6.6.7.1. Key country dynamics
- 6.6.7.2. Regulatory framework/ reimbursement structure
- 6.6.7.3. Competitive scenario
- 6.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.8. Sweden
- 6.6.8.1. Key country dynamics
- 6.6.8.2. Regulatory framework/ reimbursement structure
- 6.6.8.3. Competitive scenario
- 6.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.6.9. Denmark
- 6.6.9.1. Key country dynamics
- 6.6.9.2. Regulatory framework/ reimbursement structure
- 6.6.9.3. Competitive scenario
- 6.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.7.2. China
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.7.3. India
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.7.4. South Korea
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.7.5. Australia
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Regulatory framework/ reimbursement structure
- 6.7.5.3. Competitive scenario
- 6.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.7.6. Thailand
- 6.7.6.1. Key country dynamics
- 6.7.6.2. Regulatory framework/ reimbursement structure
- 6.7.6.3. Competitive scenario
- 6.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Key country dynamics
- 6.8.1.2. Regulatory framework/ reimbursement structure
- 6.8.1.3. Competitive scenario
- 6.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.8.2. Argentina
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Regulatory framework/ reimbursement structure
- 6.8.2.3. Competitive scenario
- 6.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Key country dynamics
- 6.9.1.2. Regulatory framework/ reimbursement structure
- 6.9.1.3. Competitive scenario
- 6.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.9.2. Saudi Arabia
- 6.9.2.1. Key country dynamics
- 6.9.2.2. Regulatory framework/ reimbursement structure
- 6.9.2.3. Competitive scenario
- 6.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.9.3. UAE
- 6.9.3.1. Key country dynamics
- 6.9.3.2. Regulatory framework/ reimbursement structure
- 6.9.3.3. Competitive scenario
- 6.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
- 6.9.4. Kuwait
- 6.9.4.1. Key country dynamics
- 6.9.4.2. Regulatory framework/ reimbursement structure
- 6.9.4.3. Competitive scenario
- 6.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis by Key Market Participants
- 7.2. Company Categorization
- 7.3. Global Company Market Share Analysis, 2025
- 7.4. Company Heat Map Analysis
- 7.5. Strategy Mapping
- 7.5.1. Expansion
- 7.5.2. Mergers & Acquisition
- 7.5.3. Partnerships & Collaborations
- 7.5.4. New Product Launches
- 7.5.5. Research And Development
- 7.6. Company Profiles
- 7.6.1. F. Hoffmann-La Roche Ltd.
- 7.6.1.1. Company overview
- 7.6.1.2. Financial performance
- 7.6.1.3. Product benchmarking
- 7.6.1.4. Strategic initiatives
- 7.6.2. Qiagen
- 7.6.2.1. Company overview
- 7.6.2.2. Financial performance
- 7.6.2.3. Product benchmarking
- 7.6.2.4. Strategic initiatives
- 7.6.3. Danaher Corporation
- 7.6.3.1. Company overview
- 7.6.3.2. Financial performance
- 7.6.3.3. Product benchmarking
- 7.6.3.4. Strategic initiatives
- 7.6.4. Becton Dickinson (BD)
- 7.6.4.1. Company overview
- 7.6.4.2. Financial performance
- 7.6.4.3. Product benchmarking
- 7.6.4.4. Strategic initiatives
- 7.6.5. bioMérieux
- 7.6.5.1. Company overview
- 7.6.5.2. Financial performance
- 7.6.5.3. Product benchmarking
- 7.6.5.4. Strategic initiatives
- 7.6.6. Abbott
- 7.6.6.1. Company overview
- 7.6.6.2. Financial performance
- 7.6.6.3. Product benchmarking
- 7.6.6.4. Strategic initiatives
- 7.6.7. Siemens Healthcare GmbH
- 7.6.7.1. Company overview
- 7.6.7.2. Financial performance
- 7.6.7.3. Product benchmarking
- 7.6.7.4. Strategic initiatives
- 7.6.8. Werfen
- 7.6.8.1. Company overview
- 7.6.8.2. Financial performance
- 7.6.8.3. Product benchmarking
- 7.6.8.4. Strategic initiatives
- 7.6.9. Nova Biomedical
- 7.6.9.1. Company overview
- 7.6.9.2. Financial performance
- 7.6.9.3. Product benchmarking
- 7.6.9.4. Strategic initiatives
- 7.6.10. Trividia Health, Inc.
- 7.6.10.1. Company overview
- 7.6.10.2. Financial performance
- 7.6.10.3. Product benchmarking
- 7.6.10.4. Strategic initiatives
- 7.6.11. QuidelOrtho Corporation
- 7.6.11.1. Company overview
- 7.6.11.2. Financial performance
- 7.6.11.3. Product benchmarking
- 7.6.11.4. Strategic initiatives
- 7.6.12. Trinity Biotech
- 7.6.12.1. Company overview
- 7.6.12.2. Financial performance
- 7.6.12.3. Product benchmarking
- 7.6.12.4. Strategic initiatives
- 7.6.13. Sekisui Diagnostics
- 7.6.13.1. Company overview
- 7.6.13.2. Financial performance
- 7.6.13.3. Product benchmarking
- 7.6.13.4. Strategic initiatives
- 7.6.14. Orasure Technologies, Inc.
- 7.6.14.1. Company overview
- 7.6.14.2. Financial performance
- 7.6.14.3. Product benchmarking
- 7.6.14.4. Strategic initiatives
- 7.6.15. Spectral Medical, Inc.
- 7.6.15.1. Company overview
- 7.6.15.2. Financial performance
- 7.6.15.3. Product benchmarking
- 7.6.15.4. Strategic initiatives
- 7.6.16. EKF Diagnostics Holdings plc.
- 7.6.16.1. Company overview
- 7.6.16.2. Financial performance
- 7.6.16.3. Product benchmarking
- 7.6.16.4. Strategic initiatives
- 7.6.17. Anbio Biotechnology Co., Ltd.
- 7.6.17.1. Company overview
- 7.6.17.2. Financial performance
- 7.6.17.3. Product benchmarking
- 7.6.17.4. Strategic initiatives
- 7.6.18. AccuBioTech Co., Ltd
- 7.6.18.1. Company overview
- 7.6.18.2. Financial performance
- 7.6.18.3. Product benchmarking
- 7.6.18.4. Strategic initiatives
- 7.6.19. ALPHA LABORATORIES
- 7.6.19.1. Company overview
- 7.6.19.2. Financial performance
- 7.6.19.3. Product benchmarking
- 7.6.19.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
